Venus Remedies appoints Ekta S Chaudhary as Chairperson of Venus Foundation

IMT News Desk
IMT News Desk
· 2 min read

To spearhead its CSR initiatives 

Venus Remedies has appointed Ekta S Chaudhary as the Chairperson of Venus Foundation, the dedicated social impact arm of the organisation. 

Chaudhary will drive the company’s corporate social responsibility (CSR) agenda, focusing on healthcare access, educational advancement, and inclusive community development. Her appointment marks a significant step in strengthening the Foundation’s impact-driven initiatives aligned with Venus Remedies’ core values of equity, empowerment and environmental stewardship. 

“Her vision, dedication, and global perspective make her uniquely positioned to lead our mission of creating meaningful and sustainable social change. I am confident her leadership will accelerate our efforts in areas such as women’s empowerment and healthcare equity,” said Pawan Chaudhary, CMD, Venus Remedies.

“Joining Venus Foundation is a unique opportunity to work alongside a purpose-driven team committed to operational excellence and social progress. I look forward to advancing the company’s CSR footprint by fostering a culture of inclusive growth. Together, we aim to build enduring partnerships and programs that empower individuals to lead change in their communities,” said Ekta S Chaudhary, Chairperson, Venus Foundation. 

A microbiologist by qualification, Chaudhary holds a degree from the University of Nottingham, a leading Russell Group institution in the UK. A passionate advocate for environmental action, she played a key role in launching Earthfest—London’s first large-scale sustainability festival—bringing together change makers, innovators, and thought leaders to raise awareness about climate action and responsible living. With early experience in the biotech and AI space in London, she is now channelling her global exposure and scientific perspective into purpose-driven work, marking the beginning of her journey in corporate social responsibility and community impact. 

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk